Anti-human OX40L antibodies and methods of treating graft versus host disease with the same

A method of treating or preventing graft versus host disease (GvHD) in a human subject in need thereof, comprising:

• administering an anti-OX40L antibody or fragment thereof that antagonizes specific binding of OX40 to OX40L to a subject determined to have a ratio of CD45RA+CCR7+CD95+OX40+ T stem cell memory (Tscm):CD45RA+CCR7+CD95− T-naive (Tn) cells greater than 50:50 wherein the antibody of fragment thereof is administered in an amount effective to reduce the ratio of said Tscm cells in said human, wherein the antibody or antibody fragment competes for binding of OX40L with an antibody comprising the VH sequence of SEQ ID NO:
• 34 and the VL sequence of SEQ ID NO:
• 48.

A method of treating or preventing graft versus host disease (GvHD) in a human subject in need thereof, comprising:

• administering an anti-OX40L antibody or fragment thereof that antagonizes specific binding of OX40 to OX40L to a subject determined to have a ratio of CD45RA+CCR7+CD95+OX40+ T stem cell memory (Tscm):
• CD45RA+CCR7+CD95− T-naive (Tn) cells greater than 50:50 wherein the antibody or fragment thereof is administered in an amount effective to reduce the ratio of said Tscm cells in said human, wherein the antibody comprises the VH sequence of SEQ ID No:215 and the VL sequence of SEQ ID No:214.

A method of preventing or treating graft versus host disease, comprising:

• a. obtaining at least two T-cell samples derived from a subject who has or is at risk of graft versus host disease, wherein said at least two T-cell samples comprise a first sample taken at a first time point and a second sample taken at a second time point after the time first sample has been taken,
• b. determining levels of CD45RA+CCR7+CD95+OX40+ Tscm cells in said first and second samples;
• c. treating said subject to reduce the proportion of CD45RA+CCR7+CD95+OX40+ Tscm cells compared to said second sample by administering an anti-OX40L antibody or antibody fragment thereof in an amount effective to reduce the levels of Tscm cells, when the level of Tscm cells in said second sample are elevated as compared to said first sample, in order to treat or prevent said graft versus host disease.